---
title: "Panlong Pharmaceutical: The net profit for the third quarter was 29.6707 million yuan, a decrease of 0.83%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262867288.md"
description: "Panlong Pharmaceutical announced that its revenue for the third quarter was 267 million yuan, a year-on-year increase of 2.24%; net profit was 29.6707 million yuan, a decrease of 0.83%. Revenue for the first three quarters was 841 million yuan, a year-on-year increase of 17.37%; net profit was 89.8059 million yuan, an increase of 0.26%"
datetime: "2025-10-27T10:17:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262867288.md)
  - [en](https://longbridge.com/en/news/262867288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262867288.md)
generator: "portal-rs"
---

# Panlong Pharmaceutical: The net profit for the third quarter was 29.6707 million yuan, a decrease of 0.83%

Panlong Pharmaceutical announced that its revenue for the third quarter was 267 million yuan, a year-on-year increase of 2.24%; net profit was 29.6707 million yuan, a decrease of 0.83%. Revenue for the first three quarters was 841 million yuan, a year-on-year increase of 17.37%; net profit was 89.8059 million yuan, an increase of 0.26%

### Related Stocks

- [002864.CN](https://longbridge.com/en/quote/002864.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [This Former Small-Cap Darling Is in Freefall, But I Like the Stock Here](https://longbridge.com/en/news/296374899.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Is it still protectionism when a national champion is part foreign-owned?](https://longbridge.com/en/news/296408762.md)
- [OncoZenge registers 772,797 shares in directed issue after SEK 5 million payment from Sichuan Yangtian](https://longbridge.com/en/news/296607308.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**